Tag: direct oral anticoagulants (doacs) device market

Built to provide research that’s more actionable and strategically valuable, The Business Research Company’s 2026 market reports include market attractiveness analysis, total addressable market sizing, company benchmarking matrices, interactive Excel dashboards, broader supply chain intelligence, emerging startup tracking, and in-depth product insights.

Direct Oral Anticoagulants (DOACs) Device Market Poised To Hit $49.48 Billion By 2030 With A 8.5% CAGR

The direct oral anticoagulants (doacs) device market has experienced significant expansion in recent years. It is forecast to rise from $32.8 billion in 2025 to $35.69 billion in 2026, exhibiting a compound annual growth rate (CAGR) of 8.8%. The growth observed in previous periods was driven by factors such as the limited access to doac monitoring equipment, the reliance on hospital-based coagulation assessments, the increasing incidence of atrial fibrillation and thrombotic conditions, the widespread adoption of oral anticoagulant treatments, and a heightened focus on patient safety and effective anticoagulation monitoring.

The market for direct oral anticoagulants (doacs) devices is projected to experience substantial expansion over the forthcoming years. This market is anticipated to reach a valuation of $49.48 billion by 2030, demonstrating a compound annual growth rate (CAGR) of 8.5%. Several factors are expected to fuel this growth during the projection period, including progress in portable and point-of-care device technologies, the integration of digital health platforms with cloud-based monitoring solutions, a growing preference for personalized anticoagulation management, the expansion of services in homecare and specialized clinics, and a rise in regulatory endorsements for new monitoring systems. Key trends anticipated during the forecast encompass a greater embrace of point-of-care doac monitoring devices, an increased application of factor Xa and direct thrombin inhibitor monitoring, heightened public awareness regarding stroke and thromboembolism prevention, the broadening of homecare and ambulatory monitoring options, and a reinforced emphasis on improving accuracy, sensitivity, and speed in testing.

Get A Free Sample Report With In-Depth Market Insights:

https://thebusinessresearchcompany.com/sample_request?id=96455245&type=smp&name=Direct%20Oral%20Anticoagulants%20%28DOACs%29%20Device%20Market%20Report%202026&utm_source=Blogs&utm_medium=Paid&utm_campaign=Oct_PR

Direct Oral Anticoagulants (DOACs) Device Market Demand Drivers Opening New Revenue Streams

The expanding occurrence of cardiovascular conditions is projected to boost the growth of the direct oral anticoagulants (DOACs) device market in the future. Cardiovascular disorders encompass various ailments affecting the heart and blood vessels, frequently resulting in complications like heart attacks, strokes, or other circulatory issues. These disorders are escalating due to progressively inactive lifestyles, contributing to weight gain, heightened blood pressure, and a gradual decline in cardiovascular function. Direct oral anticoagulants (DOACs) assist in managing cardiovascular disorders by effectively reducing the likelihood of stroke and blood clots in individuals with atrial fibrillation, providing dependable anticoagulation without requiring regular blood tests. For example, in October 2024, data from the Centers for Disease Control and Prevention, a US-based government agency, indicated that in 2023, cardiovascular disease was responsible for 919,032 lives lost, representing one in every three deaths. Coronary heart disease continued to be the most common type of heart disease, and notably, approximately one in six cardiovascular disease fatalities affected adults younger than 65 years. Consequently, the rising occurrence of cardiovascular disorders is propelling the expansion of the direct oral anticoagulants (DOACs) device market.

Direct Oral Anticoagulants (DOACs) Device Market Segment Trends And Revenue Contributors

The direct oral anticoagulants (doacs) device market covered in this report is segmented –

1) By Product: Factor Xa Inhibitors, Direct Thrombin Inhibitors

2) By Disease: Atrial Fibrillation, Deep Vein Thrombosis, Pulmonary Embolism, Heart Attacks, Post-Surgical Thromboprophylaxis, Other Diseases

3) By Application: Stroke Prevention, Venous Thromboembolism Prevention, Treatment Of Acute Thrombotic Events, Long-Term Prophylaxis, Other Applications

4) By End User: Hospitals, Ambulatory Surgical Centers, Specialty Clinics, Homecare Settings, Other End Users

Subsegments:

1) By Factor Xa Inhibitors: Rivaroxaban Monitoring Devices, Apixaban Monitoring Devices, Edoxaban Monitoring Devices, Betrixaban Monitoring Devices

2) By Direct Thrombin Inhibitors: Dabigatran Etexilate, Dabigatran Mesylate

Direct Oral Anticoagulants (DOACs) Device Market Trends Powering Strategic Industry Growth

Leading companies within the direct oral anticoagulants (DOACs) device market are concentrating on developing advanced solutions, such as automated coagulation assays, to enhance the accuracy, efficiency, and consistency of direct oral anticoagulant level monitoring in clinical laboratories. Automated coagulation assays are laboratory tests performed by machines that measure how quickly blood clots, aiding in the diagnosis of bleeding or clotting disorders. For instance, in February 2024, Roche Holding AG, a Switzerland-based pharmaceutical company, introduced three new coagulation tests specifically tailored for Factor Xa inhibitors. These tests improve clinicians’ capability to accurately evaluate the anticoagulation status of patients taking direct Factor Xa inhibitors like rivaroxaban and apixaban. They support clinical decision-making by precisely measuring the anti-Xa activity of apixaban, edoxaban, rivaroxaban, and heparin in critical scenarios such as bleeding, overdose, or urgent surgery. Utilizing Roche’s reagent cassette technology on cobas t analyzers, these automated tests deliver high-quality results, minimize manual handling, and streamline laboratory workflow efficiency.

Direct Oral Anticoagulants (DOACs) Device Market Competitive Landscape: Who Leads The Industry?

Major companies operating in the direct oral anticoagulants (doacs) device market are Pfizer Inc., Roche Diagnostics Corporation, Bristol-Myers Squibb Company, Siemens Healthcare GmbH, Becton Dickinson And Company, Boehringer Ingelheim International GmbH, Teva Pharmaceutical Industries Limited, Daiichi Sankyo Co. Ltd, Sysmex Corporation, Dr. Reddy’s Laboratories Limited, Werfen S.A., Alembic Pharmaceuticals Limited, Diagnostica Stago SAS, Helena Laboratories Corporation, iLine Microsystems S.L., Technoclone GmbH, Anthos Therapeutics Inc., FLoBio LLC, Perosphere Technologies Inc., DOASENSE GmbH.

View The Full Direct Oral Anticoagulants (DOACs) Device Market Report:

https://thebusinessresearchcompany.com/report/direct-oral-anticoagulants-doacs-device-global-market-report?utm_source=Blogs&utm_medium=Paid&utm_campaign=Oct_PR

Direct Oral Anticoagulants (DOACs) Device Market Geographic Landscape: Which Region Leads Industry Growth?

North America was the largest region in the direct oral anticoagulants (DOACs) device market in 2025. The regions covered in the direct oral anticoagulants (doacs) device market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Reach Out To Our Team:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas: +1 310-496-7795

Asia: +44 7882 955267 & +91 8897263534

Europe: +44 7882 955267

Email us at: marketing@tbrc.info

Follow us on:

LinkedIn: https://in.linkedin.com/company/the-business-research-company

YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model

The Business Research Company’s 2026 market reports feature enhanced tools like market attractiveness analysis, TAM assessment, and company scoring matrices, along with interactive dashboards, deeper supply chain insights, and startup coverage strengthening the depth, usability, and strategic value of insights.

How Much Growth In Market Value Is Expected For The Direct Oral Anticoagulants (DOACs) Device Market Between 2026 And 2030?

The direct oral anticoagulants (doacs) device market size has demonstrated significant expansion in recent years. It is anticipated to increase from $32.8 billion in 2025 to $35.69 billion in 2026, exhibiting a compound annual growth rate (CAGR) of 8.8%. This historical growth can be attributed to factors like the constrained availability of doac monitoring devices, the established dependence on hospital-based coagulation tests, the escalating prevalence of atrial fibrillation and thrombotic disorders, the wider adoption of oral anticoagulant therapies, and a heightened focus on patient safety and anticoagulation monitoring.

The direct oral anticoagulants (doacs) device market size is anticipated to experience substantial growth in the coming years. It is projected to expand to $49.48 billion by 2030, with a compound annual growth rate (CAGR) of 8.5%. The growth during this forecast period can be attributed to advancements in portable and point-of-care devices, the integration with digital health platforms and cloud-based monitoring, a rising adoption of personalized anticoagulation management, the expansion of homecare and specialty clinic services, and increasing regulatory approvals for novel monitoring systems. Key trends anticipated in the forecast period include the growing adoption of point-of-care doac monitoring devices, increasing use of factor xa and direct thrombin inhibitor monitoring, rising awareness of stroke and thromboembolism prevention, the expansion of homecare and ambulatory monitoring solutions, and an enhanced focus on accuracy, sensitivity, and rapid testing capabilities.

Access Your Free Sample Report For In-Depth Market Analysis:

https://www.thebusinessresearchcompany.com/sample.aspx?id=27281&type=smp

What Key Factors Are Affecting The Direct Oral Anticoagulants (DOACs) Device Market Demand?

The anticipated expansion of the direct oral anticoagulants (DOACs) device market is primarily fueled by the rising occurrence of cardiovascular disorders. These disorders encompass various ailments affecting the heart and blood vessels, frequently resulting in complications like heart attacks, strokes, or other circulatory problems. A key factor in the surge of cardiovascular disorders is the growing adoption of sedentary lifestyles, which contribute to weight gain, increased blood pressure, and the gradual deterioration of cardiovascular health. Direct oral anticoagulants (DOACs) play a crucial role in managing these conditions by significantly reducing the risk of stroke and blood clot formation in individuals suffering from atrial fibrillation, providing dependable anticoagulation without requiring routine blood tests. For example, data from October 2024 released by the Centers for Disease Control and Prevention, a US-based government agency, indicated that in 2023, cardiovascular disease was responsible for 919,032 lives, representing one in every three deaths. Coronary heart disease remained the most common type of heart ailment, and notably, approximately one in six deaths due to cardiovascular diseases occurred among adults younger than 65 years. Consequently, the escalating incidence of cardiovascular disorders is a significant catalyst for the expansion of the direct oral anticoagulants (DOACs) device market.

How Is Segmentation Applied In The Direct Oral Anticoagulants (DOACs) Device Market Segment Analysis?

The direct oral anticoagulants (doacs) device market covered in this report is segmented –

1) By Product: Factor Xa Inhibitors, Direct Thrombin Inhibitors

2) By Disease: Atrial Fibrillation, Deep Vein Thrombosis, Pulmonary Embolism, Heart Attacks, Post-Surgical Thromboprophylaxis, Other Diseases

3) By Application: Stroke Prevention, Venous Thromboembolism Prevention, Treatment Of Acute Thrombotic Events, Long-Term Prophylaxis, Other Applications

4) By End User: Hospitals, Ambulatory Surgical Centers, Specialty Clinics, Homecare Settings, Other End Users

Subsegments:

1) By Factor Xa Inhibitors: Rivaroxaban Monitoring Devices, Apixaban Monitoring Devices, Edoxaban Monitoring Devices, Betrixaban Monitoring Devices

2) By Direct Thrombin Inhibitors: Dabigatran Etexilate, Dabigatran Mesylate

What Trends Are Influencing Changes In The Direct Oral Anticoagulants (DOACs) Device Market?

Leading companies within the direct oral anticoagulants (DOACs) device market are concentrating on creating sophisticated solutions, such as automated coagulation assays, aimed at enhancing the precision, effectiveness, and uniformity of direct oral anticoagulant level tracking in clinical settings. These automated coagulation assays represent machine-conducted laboratory analyses that determine the rate of blood clotting, assisting in the diagnosis of bleeding or clotting conditions. An illustration of this is Roche Holding AG, a Switzerland-based pharmaceutical company, which introduced three novel coagulation tests in February 2024, specifically tailored for Factor Xa inhibitors. These offerings improve clinicians’ capacity to precisely assess the anticoagulation state of individuals on direct Factor Xa inhibitors like rivaroxaban and apixaban. They support clinical judgments by accurately quantifying the anti-Xa activity of apixaban, edoxaban, rivaroxaban, and heparin during crucial situations such as bleeding episodes, overdoses, or impending surgeries. Leveraging Roche’s reagent cassette technology on cobas t analyzers, these automated diagnostics yield superior results, reduce the need for manual intervention, and optimize the efficiency of laboratory operations.

Who Are The Companies Participating In The Direct Oral Anticoagulants (DOACs) Device Market Environment?

Major companies operating in the direct oral anticoagulants (doacs) device market are Pfizer Inc., Roche Diagnostics Corporation, Bristol-Myers Squibb Company, Siemens Healthcare GmbH, Becton Dickinson And Company, Boehringer Ingelheim International GmbH, Teva Pharmaceutical Industries Limited, Daiichi Sankyo Co. Ltd, Sysmex Corporation, Dr. Reddy’s Laboratories Limited, Werfen S.A., Alembic Pharmaceuticals Limited, Diagnostica Stago SAS, Helena Laboratories Corporation, iLine Microsystems S.L., Technoclone GmbH, Anthos Therapeutics Inc., FLoBio LLC, Perosphere Technologies Inc., DOASENSE GmbH.

Get The Full Direct Oral Anticoagulants (DOACs) Device Market Report:

https://www.thebusinessresearchcompany.com/report/direct-oral-anticoagulants-doacs-device-global-market-report

Which Region Leads The Direct Oral Anticoagulants (DOACs) Device Market In Terms Of Market Share?

North America was the largest region in the direct oral anticoagulants (DOACs) device market in 2025. The regions covered in the direct oral anticoagulants (doacs) device market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Request A Customized Direct Oral Anticoagulants (DOACs) Device Market Report For Competitive Insights:

https://www.thebusinessresearchcompany.com/customise?id=27281&type=smp

Browse Through More Reports Similar to the Global Direct Oral Anticoagulants (DOACs) Device Market 2026, By The Business Research Company

Machine Learning Market Report 2026

https://www.thebusinessresearchcompany.com/report/machine-learning-global-market-report

Financial Analytics Market Report 2026

https://www.thebusinessresearchcompany.com/report/financial-analytics-global-market-report

Machine Learning Ml In The Pharmaceutical Industry Market Report 2026

https://www.thebusinessresearchcompany.com/report/machine-learning-ml-in-the-pharmaceutical-industry-global-market-report

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas +1 310-496-7795

Asia +44 7882 955267 & +91 8897263534

Europe +44 7882 955267

Email us at info@tbrc.info

Follow us on:

LinkedIn: https://in.linkedin.com/company/the-business-research-company

YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model

The Business Research Company’s 2026 market reports include new capabilities such as market attractiveness scoring and analysis, total addressable market analysis, company scoring matrix, interactive excel data dashboard, improved supply chain analysis, upcoming startups in the market, and overview of key products, aimed at improving the depth, usability, and strategic value of the insights delivered.

What Will Be The Estimated Market Valuation Of The Direct Oral Anticoagulants (DOACs) Device Market By The End Of 2030?

The direct oral anticoagulants (doacs) device market has experienced significant growth in recent years. It will grow from $32.8 billion in 2025 to $35.69 billion in 2026 at a compound annual growth rate (CAGR) of 8.8%. Factors contributing to its historical expansion include the limited availability of doac monitoring devices, a reliance on hospital-based coagulation tests, the growing prevalence of atrial fibrillation and thrombotic disorders, the adoption of oral anticoagulant therapies, and an increasing demand for patient safety and effective anticoagulation monitoring.

The direct oral anticoagulants (DOACs) device market size is projected to experience significant growth in the coming years. It is expected to expand to $49.48 billion in 2030, demonstrating a compound annual growth rate (CAGR) of 8.5%. This growth during the forecast period is driven by factors such as technological progress in portable and point-of-care devices, the integration with digital health platforms and cloud-based monitoring, increasing adoption of personalized anticoagulation management, the expansion of homecare and specialty clinic services, and a rise in regulatory approvals for innovative monitoring systems. Prominent trends for the forecast period include the expanding use of point-of-care DOAC monitoring devices, a greater focus on factor Xa and direct thrombin inhibitor monitoring, growing awareness regarding stroke and thromboembolism prevention, the development of homecare and ambulatory monitoring solutions, and an enhanced emphasis on accuracy, sensitivity, and rapid testing capabilities.

Download the Free Sample Report to Explore Key Market Insights:

https://www.thebusinessresearchcompany.com/sample.aspx?id=27281&type=smp

What Primary Drivers Are Shaping The Development Of The Direct Oral Anticoagulants (DOACs) Device Market?

The rising occurrence of cardiovascular conditions is projected to boost the expansion of the direct oral anticoagulants (DOACs) device market in the future. These disorders encompass various ailments affecting the heart and blood vessels, frequently resulting in complications like heart attacks, strokes, or other circulatory issues. An increase in cardiovascular disorders is linked to increasingly sedentary lifestyles, which contribute to weight gain, higher blood pressure, and a gradual decline in cardiovascular function. Direct oral anticoagulants (DOACs) assist in managing cardiovascular disorders by effectively reducing the risk of stroke and blood clots in individuals with atrial fibrillation, providing dependable anticoagulation without requiring frequent blood tests. For example, in October 2024, the Centers for Disease Control and Prevention, a US-based government agency, reported that in 2023, cardiovascular disease was responsible for 919,032 lives, representing one in every three deaths. Coronary heart disease continued to be the most common type of heart disease, and it was notable that approximately one in six deaths from cardiovascular diseases affected adults younger than 65 years. Consequently, the growing prevalence of cardiovascular disorders is propelling the growth of the direct oral anticoagulants (DOACs) device market.

Which Segment Classifications Shape The Direct Oral Anticoagulants (DOACs) Device Market?

The direct oral anticoagulants (doacs) device market covered in this report is segmented –

1) By Product: Factor Xa Inhibitors, Direct Thrombin Inhibitors

2) By Disease: Atrial Fibrillation, Deep Vein Thrombosis, Pulmonary Embolism, Heart Attacks, Post-Surgical Thromboprophylaxis, Other Diseases

3) By Application: Stroke Prevention, Venous Thromboembolism Prevention, Treatment Of Acute Thrombotic Events, Long-Term Prophylaxis, Other Applications

4) By End User: Hospitals, Ambulatory Surgical Centers, Specialty Clinics, Homecare Settings, Other End Users

Subsegments:

1) By Factor Xa Inhibitors: Rivaroxaban Monitoring Devices, Apixaban Monitoring Devices, Edoxaban Monitoring Devices, Betrixaban Monitoring Devices

2) By Direct Thrombin Inhibitors: Dabigatran Etexilate, Dabigatran Mesylate

How Are Trends Impacting The Direct Oral Anticoagulants (DOACs) Device Market?

Leading firms within the direct oral anticoagulants (DOACs) device market are concentrating on creating sophisticated solutions, like automated coagulation assays, aiming to enhance the precision, effectiveness, and uniformity of direct oral anticoagulant level surveillance within clinical lab settings. These automated coagulation assays are machine-conducted laboratory examinations designed to assess the speed of blood clotting, assisting in the diagnosis of various bleeding or clotting conditions. As an illustration, in February 2024, Roche Holding AG, a pharmaceutical company based in Switzerland, introduced three novel coagulation tests tailored for Factor Xa inhibitors. These tests improve clinicians’ capability to precisely assess the anticoagulation state of patients using direct Factor Xa inhibitors like rivaroxaban and apixaban. They support clinical decisions by accurately quantifying the anti-Xa activity of apixaban, edoxaban, rivaroxaban, and heparin during crucial situations such as bleeding events, overdoses, or emergency surgical procedures. Employing Roche’s reagent cassette technology on cobas t analyzers, these automated examinations provide superior results, reduce the need for manual intervention, and optimize the efficiency of laboratory workflows.

Which Companies Are Expanding Their Footprint In The Direct Oral Anticoagulants (DOACs) Device Market?

Major companies operating in the direct oral anticoagulants (doacs) device market are Pfizer Inc., Roche Diagnostics Corporation, Bristol-Myers Squibb Company, Siemens Healthcare GmbH, Becton Dickinson And Company, Boehringer Ingelheim International GmbH, Teva Pharmaceutical Industries Limited, Daiichi Sankyo Co. Ltd, Sysmex Corporation, Dr. Reddy’s Laboratories Limited, Werfen S.A., Alembic Pharmaceuticals Limited, Diagnostica Stago SAS, Helena Laboratories Corporation, iLine Microsystems S.L., Technoclone GmbH, Anthos Therapeutics Inc., FLoBio LLC, Perosphere Technologies Inc., DOASENSE GmbH.

Read the full direct oral anticoagulants (doacs) device market report here:

https://www.thebusinessresearchcompany.com/report/direct-oral-anticoagulants-doacs-device-global-market-report

How Does The Direct Oral Anticoagulants (DOACs) Device Market Perform Across Major Global Regions?

North America was the largest region in the direct oral anticoagulants (DOACs) device market in 2025. The regions covered in the direct oral anticoagulants (doacs) device market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Request A Tailored Direct Oral Anticoagulants (DOACs) Device Market Research Report For Competitive Advantage:

https://www.thebusinessresearchcompany.com/customise?id=27281&type=smp

Browse Through More Reports Similar to the Global Direct Oral Anticoagulants (DOACs) Device Market 2026, By The Business Research Company

Machine Learning Market Report 2026

https://www.thebusinessresearchcompany.com/report/machine-learning-global-market-report

Financial Analytics Market Report 2026

https://www.thebusinessresearchcompany.com/report/financial-analytics-global-market-report

Machine Learning Ml In The Pharmaceutical Industry Market Report 2026

https://www.thebusinessresearchcompany.com/report/machine-learning-ml-in-the-pharmaceutical-industry-global-market-report

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas +1 310-496-7795

Asia +44 7882 955267 & +91 8897263534

Europe +44 7882 955267

Email us at info@tbrc.info

Follow us on:

LinkedIn: https://in.linkedin.com/company/the-business-research-company

YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model

Uncover key drivers, emerging technologies, and competitive movements shaping the worker heat stress monitoring wearable market from 2026–2035 with trusted insights from The Business Research Company

How much is the Direct Oral Anticoagulants (DOACs) Device Market valued at in 2026, and what valuation is forecast for 2030?

The direct oral anticoagulants (doacs) device market has demonstrated substantial growth in recent years. This market is projected to expand from $32.8 billion in 2025 to $35.69 billion in 2026, achieving a compound annual growth rate (CAGR) of 8.8%. The growth observed in the past can be attributed to aspects such as the limited availability of doac monitoring devices, a reliance on hospital-based coagulation tests, the growing prevalence of atrial fibrillation and thrombotic disorders, the adoption of oral anticoagulant therapies, and an increasing demand for patient safety and anticoagulation monitoring.

The direct oral anticoagulants (doacs) device market is projected to experience substantial expansion in the coming years. This market is anticipated to reach $49.48 billion by 2030, exhibiting a compound annual growth rate (CAGR) of 8.5%. Factors driving this growth during the forecast period include technological improvements in portable and point-of-care devices, the incorporation of digital health platforms alongside cloud-based monitoring, increasing acceptance of personalized anticoagulation management, the expansion of homecare and specialized clinic services, and a rise in regulatory approvals for new monitoring systems. Key trends emerging over the forecast horizon encompass a greater uptake of point-of-care doac monitoring devices, an expanding utilization of factor xa and direct thrombin inhibitor monitoring, heightened awareness regarding stroke and thromboembolism prevention, the broadening of homecare and ambulatory monitoring solutions, and an intensified emphasis on precision, sensitivity, and swift testing capabilities.

Access Your Free Sample Report for In-Depth Market Insights:

https://www.thebusinessresearchcompany.com/sample.aspx?id=27281&type=smp

What Drivers Are Influencing The Growth Of The Direct Oral Anticoagulants (DOACs) Device Market?

The growing occurrence of cardiovascular conditions is projected to boost the expansion of the direct oral anticoagulants (DOACs) device market in the future. These conditions encompass various ailments affecting the heart and blood vessels, frequently resulting in problems such as heart attacks, strokes, or other circulatory issues. The increase in cardiovascular disorders is linked to more sedentary ways of life, which contribute to weight gain, higher blood pressure, and a gradual weakening of cardiovascular function. Direct oral anticoagulants (DOACs) aid in addressing cardiovascular disorders by efficiently reducing the risk of stroke and blood clots for individuals with atrial fibrillation, providing dependable anticoagulation without requiring regular blood tests. As an illustration, in October 2024, data from the Centers for Disease Control and Prevention, a US-based government agency, indicated that in 2023, cardiovascular disease was responsible for 919,032 lives, making up one in every three deaths. Coronary heart disease continued to be the most common type of heart disease, and significantly, roughly one in six deaths attributed to cardiovascular diseases affected adults under 65 years. Consequently, the rising incidence of cardiovascular disorders is fueling the growth of the direct oral anticoagulants (DOACs) device market.

What Segments Are Included Within The Direct Oral Anticoagulants (DOACs) Device Market?

The direct oral anticoagulants (doacs) device market covered in this report is segmented –

1) By Product: Factor Xa Inhibitors, Direct Thrombin Inhibitors

2) By Disease: Atrial Fibrillation, Deep Vein Thrombosis, Pulmonary Embolism, Heart Attacks, Post-Surgical Thromboprophylaxis, Other Diseases

3) By Application: Stroke Prevention, Venous Thromboembolism Prevention, Treatment Of Acute Thrombotic Events, Long-Term Prophylaxis, Other Applications

4) By End User: Hospitals, Ambulatory Surgical Centers, Specialty Clinics, Homecare Settings, Other End Users

Subsegments:

1) By Factor Xa Inhibitors: Rivaroxaban Monitoring Devices, Apixaban Monitoring Devices, Edoxaban Monitoring Devices, Betrixaban Monitoring Devices

2) By Direct Thrombin Inhibitors: Dabigatran Etexilate, Dabigatran Mesylate

How Are New Market Trends Shaping The Landscape Of The Direct Oral Anticoagulants (DOACs) Device Market?

Leading companies in the direct oral anticoagulants (DOACs) device market are concentrating on developing advanced solutions, such as automated coagulation assays, to improve the accuracy, efficiency, and consistency of direct oral anticoagulant level monitoring in clinical laboratories. These automated coagulation assays are machine-operated laboratory tests that measure the speed at which blood clots, aiding in the diagnosis of bleeding or clotting disorders. For instance, in February 2024, Roche Holding AG, a Switzerland-based pharmaceutical company, introduced three new coagulation tests specifically designed for Factor Xa inhibitors. These tests enhance clinicians’ ability to accurately evaluate the anticoagulation status of patients taking direct Factor Xa inhibitors such as rivaroxaban and apixaban. They further assist clinical decision-making by precisely measuring the anti-Xa activity of apixaban, edoxaban, rivaroxaban, and heparin in critical scenarios like bleeding, overdose, or urgent surgery. Leveraging Roche’s reagent cassette technology on cobas t analyzers, these automated tests deliver high-quality results, minimize manual handling, and streamline laboratory workflow efficiency.

Who Are The Core Companies Influencing Trends In The Direct Oral Anticoagulants (DOACs) Device Market?

Major companies operating in the direct oral anticoagulants (doacs) device market are Pfizer Inc., Roche Diagnostics Corporation, Bristol-Myers Squibb Company, Siemens Healthcare GmbH, Becton Dickinson And Company, Boehringer Ingelheim International GmbH, Teva Pharmaceutical Industries Limited, Daiichi Sankyo Co. Ltd, Sysmex Corporation, Dr. Reddy’s Laboratories Limited, Werfen S.A., Alembic Pharmaceuticals Limited, Diagnostica Stago SAS, Helena Laboratories Corporation, iLine Microsystems S.L., Technoclone GmbH, Anthos Therapeutics Inc., FLoBio LLC, Perosphere Technologies Inc., DOASENSE GmbH.

Access The Complete Report For Deeper Market Insights:

https://www.thebusinessresearchcompany.com/report/direct-oral-anticoagulants-doacs-device-global-market-report

Which Geographic Areas Are Emerging As Strong Markets For The Direct Oral Anticoagulants (DOACs) Device Market?

North America was the largest region in the direct oral anticoagulants (DOACs) device market in 2025. The regions covered in the direct oral anticoagulants (doacs) device market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Request Your Customized Direct Oral Anticoagulants (DOACs) Device Market Research Report for Competitive Advantage:

https://www.thebusinessresearchcompany.com/customise?id=27281&type=smp

Browse Through More Reports Similar to the Global Direct Oral Anticoagulants (DOACs) Device Market 2026, By The Business Research Company

Machine Learning Global Market Report 2026

https://www.thebusinessresearchcompany.com/report/machine-learning-global-market-report

Financial Analytics Global Market Report 2026

https://www.thebusinessresearchcompany.com/report/financial-analytics-global-market-report

Machine Learning Ml In The Pharmaceutical Industry Global Market Report 2026

https://www.thebusinessresearchcompany.com/report/machine-learning-ml-in-the-pharmaceutical-industry-global-market-report

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas +1 310-496-7795

Asia +44 7882 955267 & +91 8897263534

Europe +44 7882 955267

Email us at info@tbrc.info

Follow us on:

LinkedIn: https://in.linkedin.com/company/the-business-research-company

Uncover key drivers, emerging technologies, and competitive movements shaping the worker heat stress monitoring wearable market from 2026–2035 with trusted insights from The Business Research Company

How much is the Direct Oral Anticoagulants (DOACs) Device Market valued at in 2026, and what valuation is forecast for 2030?_x000D_

The direct oral anticoagulants (doacs) device market has demonstrated substantial growth in recent years. This market is projected to expand from $32.8 billion in 2025 to $35.69 billion in 2026, achieving a compound annual growth rate (CAGR) of 8.8%. The growth observed in the past can be attributed to aspects such as the limited availability of doac monitoring devices, a reliance on hospital-based coagulation tests, the growing prevalence of atrial fibrillation and thrombotic disorders, the adoption of oral anticoagulant therapies, and an increasing demand for patient safety and anticoagulation monitoring._x000D_

_x000D_

The direct oral anticoagulants (doacs) device market is projected to experience substantial expansion in the coming years. This market is anticipated to reach $49.48 billion by 2030, exhibiting a compound annual growth rate (CAGR) of 8.5%. Factors driving this growth during the forecast period include technological improvements in portable and point-of-care devices, the incorporation of digital health platforms alongside cloud-based monitoring, increasing acceptance of personalized anticoagulation management, the expansion of homecare and specialized clinic services, and a rise in regulatory approvals for new monitoring systems. Key trends emerging over the forecast horizon encompass a greater uptake of point-of-care doac monitoring devices, an expanding utilization of factor xa and direct thrombin inhibitor monitoring, heightened awareness regarding stroke and thromboembolism prevention, the broadening of homecare and ambulatory monitoring solutions, and an intensified emphasis on precision, sensitivity, and swift testing capabilities._x000D_

_x000D_

#Access Your Free Sample Report for In-Depth Market Insights:#_x000D_

https://www.thebusinessresearchcompany.com/sample.aspx?id=27281&type=smp_x000D_

_x000D_

What Drivers Are Influencing The Growth Of The Direct Oral Anticoagulants (DOACs) Device Market?_x000D_

The growing occurrence of cardiovascular conditions is projected to boost the expansion of the direct oral anticoagulants (DOACs) device market in the future. These conditions encompass various ailments affecting the heart and blood vessels, frequently resulting in problems such as heart attacks, strokes, or other circulatory issues. The increase in cardiovascular disorders is linked to more sedentary ways of life, which contribute to weight gain, higher blood pressure, and a gradual weakening of cardiovascular function. Direct oral anticoagulants (DOACs) aid in addressing cardiovascular disorders by efficiently reducing the risk of stroke and blood clots for individuals with atrial fibrillation, providing dependable anticoagulation without requiring regular blood tests. As an illustration, in October 2024, data from the Centers for Disease Control and Prevention, a US-based government agency, indicated that in 2023, cardiovascular disease was responsible for 919,032 lives, making up one in every three deaths. Coronary heart disease continued to be the most common type of heart disease, and significantly, roughly one in six deaths attributed to cardiovascular diseases affected adults under 65 years. Consequently, the rising incidence of cardiovascular disorders is fueling the growth of the direct oral anticoagulants (DOACs) device market._x000D_

_x000D_

What Segments Are Included Within The Direct Oral Anticoagulants (DOACs) Device Market?_x000D_

The direct oral anticoagulants (doacs) device market covered in this report is segmented – _x000D_

_x000D_

1) By Product: Factor Xa Inhibitors, Direct Thrombin Inhibitors_x000D_

2) By Disease: Atrial Fibrillation, Deep Vein Thrombosis, Pulmonary Embolism, Heart Attacks, Post-Surgical Thromboprophylaxis, Other Diseases_x000D_

3) By Application: Stroke Prevention, Venous Thromboembolism Prevention, Treatment Of Acute Thrombotic Events, Long-Term Prophylaxis, Other Applications_x000D_

4) By End User: Hospitals, Ambulatory Surgical Centers, Specialty Clinics, Homecare Settings, Other End Users_x000D_

_x000D_

Subsegments:_x000D_

1) By Factor Xa Inhibitors: Rivaroxaban Monitoring Devices, Apixaban Monitoring Devices, Edoxaban Monitoring Devices, Betrixaban Monitoring Devices_x000D_

2) By Direct Thrombin Inhibitors: Dabigatran Etexilate, Dabigatran Mesylate_x000D_

_x000D_

How Are New Market Trends Shaping The Landscape Of The Direct Oral Anticoagulants (DOACs) Device Market?_x000D_

Leading companies in the direct oral anticoagulants (DOACs) device market are concentrating on developing advanced solutions, such as automated coagulation assays, to improve the accuracy, efficiency, and consistency of direct oral anticoagulant level monitoring in clinical laboratories. These automated coagulation assays are machine-operated laboratory tests that measure the speed at which blood clots, aiding in the diagnosis of bleeding or clotting disorders. For instance, in February 2024, Roche Holding AG, a Switzerland-based pharmaceutical company, introduced three new coagulation tests specifically designed for Factor Xa inhibitors. These tests enhance clinicians’ ability to accurately evaluate the anticoagulation status of patients taking direct Factor Xa inhibitors such as rivaroxaban and apixaban. They further assist clinical decision-making by precisely measuring the anti-Xa activity of apixaban, edoxaban, rivaroxaban, and heparin in critical scenarios like bleeding, overdose, or urgent surgery. Leveraging Roche’s reagent cassette technology on cobas t analyzers, these automated tests deliver high-quality results, minimize manual handling, and streamline laboratory workflow efficiency._x000D_

_x000D_

Who Are The Core Companies Influencing Trends In The Direct Oral Anticoagulants (DOACs) Device Market?_x000D_

Major companies operating in the direct oral anticoagulants (doacs) device market are Pfizer Inc., Roche Diagnostics Corporation, Bristol-Myers Squibb Company, Siemens Healthcare GmbH, Becton Dickinson And Company, Boehringer Ingelheim International GmbH, Teva Pharmaceutical Industries Limited, Daiichi Sankyo Co. Ltd, Sysmex Corporation, Dr. Reddy’s Laboratories Limited, Werfen S.A., Alembic Pharmaceuticals Limited, Diagnostica Stago SAS, Helena Laboratories Corporation, iLine Microsystems S.L., Technoclone GmbH, Anthos Therapeutics Inc., FLoBio LLC, Perosphere Technologies Inc., DOASENSE GmbH. _x000D_

_x000D_

#Access The Complete Report For Deeper Market Insights:#_x000D_

https://www.thebusinessresearchcompany.com/report/direct-oral-anticoagulants-doacs-device-global-market-report_x000D_

_x000D_

Which Geographic Areas Are Emerging As Strong Markets For The Direct Oral Anticoagulants (DOACs) Device Market?_x000D_

North America was the largest region in the direct oral anticoagulants (DOACs) device market in 2025. The regions covered in the direct oral anticoagulants (doacs) device market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa._x000D_

_x000D_

#Request Your Customized Direct Oral Anticoagulants (DOACs) Device Market Research Report for Competitive Advantage:#_x000D_

https://www.thebusinessresearchcompany.com/customise?id=27281&type=smp_x000D_

_x000D_

#Browse Through More Reports Similar to the Global Direct Oral Anticoagulants (DOACs) Device Market 2026, By The Business Research Company#_x000D_

_x000D_

Machine Learning Global Market Report 2026_x000D_

https://www.thebusinessresearchcompany.com/report/machine-learning-global-market-report_x000D_

_x000D_

Financial Analytics Global Market Report 2026_x000D_

https://www.thebusinessresearchcompany.com/report/financial-analytics-global-market-report_x000D_

_x000D_

Machine Learning Ml In The Pharmaceutical Industry Global Market Report 2026_x000D_

https://www.thebusinessresearchcompany.com/report/machine-learning-ml-in-the-pharmaceutical-industry-global-market-report_x000D_

_x000D_

#Get in touch with us:#_x000D_

_x000D_

The Business Research Company: https://www.thebusinessresearchcompany.com/_x000D_

Americas +1 310-496-7795_x000D_

Asia +44 7882 955267 & +91 8897263534_x000D_

Europe +44 7882 955267_x000D_

Email us at info@tbrc.info_x000D_

_x000D_

#Follow us on:#_x000D_

_x000D_

LinkedIn: https://in.linkedin.com/company/the-business-research-company_x000D_

Uncover key drivers, emerging technologies, and competitive movements shaping the direct oral anticoagulants (doacs) device market from 2025–2034 with trusted insights from The Business Research Company

What Is The Projected Valuation Of The Direct Oral Anticoagulants (DOACs) Device Market In The Coming Years?

The market size for direct oral anticoagulants (DOACs) devices has experienced robust growth in recent years. It is anticipated to expand from $30.10 billion in 2024 to $32.80 billion in 2025, at a compound annual growth rate (CAGR) of 9.0%. This historical growth can be linked to factors such as the increasing prevalence of cardiovascular disorders, a rising incidence of atrial fibrillation, enhanced awareness regarding stroke prevention, an increase in anticoagulant prescriptions, and the expanding geriatric population.

The direct oral anticoagulants (DOACs) device market size is projected to experience substantial expansion in the coming years. This market is anticipated to reach $45.65 billion by 2029, exhibiting a compound annual growth rate (CAGR) of 8.6%. Factors contributing to this growth during the forecast period include the increasing adoption of personalized medical approaches, a heightened preference for managing anticoagulation at home, a growing need for quick diagnostic instruments, increased understanding of stroke prevention, and the development of healthcare facilities in developing economies. Key trends expected during this period encompass the incorporation of smart sensors into monitoring devices, the creation of point-of-care testing solutions for direct oral anticoagulants, ongoing advancements in drug delivery methods, their integration into standard clinical practices, and technological improvements in tools designed to enhance patient adherence.

Get A Free Sample Of The Report:

https://www.thebusinessresearchcompany.com/sample.aspx?id=27281&type=smp

Which Market Dynamics Are Playing A Critical Role In The Growth Of The Direct Oral Anticoagulants (DOACs) Device Market?

The direct oral anticoagulants (DOACs) device market is projected to expand due to the escalating prevalence of cardiovascular disorders. These disorders encompass various conditions impacting the heart and blood vessels, frequently leading to issues such as heart attacks, strokes, or other circulatory problems. The rise in cardiovascular disorders is attributed to increasingly sedentary lifestyles, which contribute to weight gain, elevated blood pressure, and a gradual weakening of cardiovascular function. Direct oral anticoagulants (DOACs) play a vital role in managing cardiovascular disorders by effectively reducing the risk of stroke and blood clots in patients with atrial fibrillation, providing reliable anticoagulation without the necessity of frequent blood tests. For instance, according to the American Heart Association in January 2025, cardiovascular disease was responsible for 941,652 deaths in the US in 2022, which is over 10,000 more than the 931,578 deaths attributed to it in 2021. Consequently, the increasing prevalence of cardiovascular disorders is propelling the growth of the direct oral anticoagulants (DOACs) device market.

Which Sub-Segments Are Driving Growth Within The Direct Oral Anticoagulants (DOACs) Device Market?

The direct oral anticoagulants (DOACs) device market covered in this report is segmented

1) By Product: Factor Xa Inhibitors, Direct Thrombin Inhibitors

2) By Disease: Atrial Fibrillation, Deep Vein Thrombosis, Pulmonary Embolism, Heart Attacks, Post-Surgical Thromboprophylaxis, Other Diseases

3) By Application: Stroke Prevention, Venous Thromboembolism Prevention, Treatment Of Acute Thrombotic Events, Long-Term Prophylaxis, Other Applications

4) By End User: Hospitals, Ambulatory Surgical Centers, Specialty Clinics, Homecare Settings, Other End Users

Subsegments:

1) By Factor Xa Inhibitors: Rivaroxaban Monitoring Devices, Apixaban Monitoring Devices, Edoxaban Monitoring Devices, Betrixaban Monitoring Devices

2) By Direct Thrombin Inhibitors: Dabigatran Etexilate, Dabigatran Mesylate

What Future-Focused Trends Are Anticipated In The Direct Oral Anticoagulants (DOACs) Device Market?

Leading companies active in the direct oral anticoagulants (DOACs) device market are channeling efforts into developing advanced solutions, including automated coagulation assays, to enhance the accuracy, efficiency, and uniformity of monitoring direct oral anticoagulant levels in clinical laboratories. Automated coagulation assays are laboratory procedures performed by machines that gauge the rate at which blood clots, aiding in the identification of bleeding or clotting disorders. An example of this is Roche Holding AG, a pharmaceutical company from Switzerland, which in February 2024, unveiled three new coagulation tests specifically designed for Factor Xa inhibitors. These tests empower clinicians to more precisely evaluate the anticoagulation state of patients on direct Factor Xa inhibitors such as rivaroxaban and apixaban. They contribute to informed clinical decisions by accurately quantifying the anti-Xa activity of apixaban, edoxaban, rivaroxaban, and heparin in critical scenarios like hemorrhage, overdose, or urgent surgical interventions. Utilizing Roche’s unique reagent cassette technology on cobas t analyzers, these automated analyses deliver high-quality outcomes, minimize manual handling, and streamline laboratory operational efficiency.

Which Players Are Shaping The Competitive Landscape Of The Direct Oral Anticoagulants (DOACs) Device Market?

Major companies operating in the direct oral anticoagulants (DOACs) device market are Pfizer Inc., Roche Diagnostics Corporation, Bristol-Myers Squibb Company, Siemens Healthcare GmbH, Becton Dickinson And Company, Boehringer Ingelheim International GmbH, Teva Pharmaceutical Industries Limited, Daiichi Sankyo Co. Ltd, Sysmex Corporation, Dr. Reddy’s Laboratories Limited, Werfen S.A., Alembic Pharmaceuticals Limited, Diagnostica Stago SAS, Helena Laboratories Corporation, iLine Microsystems S.L., Technoclone GmbH, Anthos Therapeutics Inc., FLoBio LLC, Perosphere Technologies Inc., and DOASENSE GmbH.

Access The Complete Report Here:

https://www.thebusinessresearchcompany.com/report/direct-oral-anticoagulants-doacs-device-global-market-report

How Do Regional Dynamics Influence The Direct Oral Anticoagulants (DOACs) Device Market Performance?

North America was the largest region in the direct oral anticoagulants (DOACs) device market in 2024. The regions covered in the direct oral anticoagulants (DOACs) device market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Customize Your Report Here:

https://www.thebusinessresearchcompany.com/customise?id=27281&type=smp

Browse Through More Reports Similar to the Global Direct Oral Anticoagulants (DOACs) Device Market 2025, By The Business Research Company

Financial Services Global Market Report 2025

https://www.thebusinessresearchcompany.com/report/financial-services-global-market-report

Financial Analytics Global Market Report 2025

https://www.thebusinessresearchcompany.com/report/financial-analytics-global-market-report

Machine Learning Ml In The Pharmaceutical Industry Global Market Report 2025

https://www.thebusinessresearchcompany.com/report/machine-learning-ml-in-the-pharmaceutical-industry-global-market-report

About The Business Research Company:

With over 15000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Armed with 1,500,000 datasets, the optimistic contribution of in-depth secondary research, and unique insights from industry leaders, you can get the information you need to stay ahead in the game.

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas +1 310-496-7795

Asia +44 7882 955267 & +91 8897263534

Europe +44 7882 955267

Email us at info@tbrc.info

Follow us on:

LinkedIn: https://in.linkedin.com/company/the-business-research-company

YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model

Unlock Global Insights – Save 20% on Market Reports with Code ONLINE20

What Are The Forecasted Market Size Estimates For The Direct Oral Anticoagulants (DOACs) Device Market Between 2025 And 2029?

The direct oral anticoagulants (DOACs) device market size has witnessed significant expansion in recent years. It is projected to increase from $30.10 billion in 2024 to $32.80 billion in 2025, demonstrating a compound annual growth rate (CAGR) of 9.0%. This historical growth can be attributed to several factors, including the increasing prevalence of cardiovascular disorders, the rising incidence of atrial fibrillation, greater awareness regarding stroke prevention, a surge in anticoagulant prescriptions, and the growing geriatric population.

The market for direct oral anticoagulants (DOACs) devices is projected to experience substantial expansion over the upcoming years. By 2029, this market is anticipated to reach a valuation of $45.65 billion, expanding at a compound annual growth rate (CAGR) of 8.6%. Factors contributing to this growth during the forecast period include the increasing uptake of personalized medicine, a rising inclination towards managing anticoagulants at home, a heightened need for swift diagnostic instruments, greater awareness about preventing strokes, and the expanding healthcare infrastructure within developing economies. Key trends expected in the forecast timeframe encompass the incorporation of smart sensors into monitoring devices, the creation of point-of-care testing solutions for direct oral anticoagulants, ongoing advancements in drug delivery systems, their integration into standard clinical procedures, and technological improvements in tools designed to enhance patient adherence.

Unlock Your Free Sample Report for Exclusive Market Data:

https://www.thebusinessresearchcompany.com/sample.aspx?id=27281&type=smp

Which Drivers Are Supporting Growth Of The Direct Oral Anticoagulants (DOACs) Device Market?

The market for direct oral anticoagulants (DOACs) devices is projected to expand due to the rising occurrence of cardiovascular disorders. These disorders encompass various ailments affecting the heart and blood vessels, frequently resulting in complications like heart attacks, strokes, or other problems within the circulatory system. The increase in cardiovascular disorders is linked to increasingly sedentary lifestyles, which, over time, contribute to weight gain, higher blood pressure, and diminished cardiovascular function. Direct oral anticoagulants (DOACs) assist in managing cardiovascular conditions by effectively reducing the likelihood of stroke and blood clots for individuals with atrial fibrillation, providing consistent anticoagulation without requiring regular blood tests. For example, as reported in January 2025 by the American Heart Association, a US-based nonprofit organization, cardiovascular disease led to 941,652 deaths in the US in 2022, representing an increase of over 10,000 deaths compared to the 931,578 recorded in 2021. Consequently, the growing incidence of cardiovascular disorders is a key factor propelling the expansion of the direct oral anticoagulants (DOACs) device market.

What Are The Different Segment Classifications Within The Direct Oral Anticoagulants (DOACs) Device Market?

The direct oral anticoagulants (DOACs) device market covered in this report is segmented

1) By Product: Factor Xa Inhibitors, Direct Thrombin Inhibitors

2) By Disease: Atrial Fibrillation, Deep Vein Thrombosis, Pulmonary Embolism, Heart Attacks, Post-Surgical Thromboprophylaxis, Other Diseases

3) By Application: Stroke Prevention, Venous Thromboembolism Prevention, Treatment Of Acute Thrombotic Events, Long-Term Prophylaxis, Other Applications

4) By End User: Hospitals, Ambulatory Surgical Centers, Specialty Clinics, Homecare Settings, Other End Users

Subsegments:

1) By Factor Xa Inhibitors: Rivaroxaban Monitoring Devices, Apixaban Monitoring Devices, Edoxaban Monitoring Devices, Betrixaban Monitoring Devices

2) By Direct Thrombin Inhibitors: Dabigatran Etexilate, Dabigatran Mesylate

Which Key Trends Are Expected To Influence The Direct Oral Anticoagulants (DOACs) Device Market In The Coming Years?

Leading companies within the direct oral anticoagulants (DOACs) device market are concentrating on developing sophisticated solutions, notably automated coagulation assays, to enhance the accuracy, efficiency, and consistency of direct oral anticoagulant level monitoring in clinical laboratories. These automated coagulation assays are machine-performed laboratory tests that gauge blood clotting speed, assisting in the diagnosis of bleeding or clotting disorders. For example, in February 2024, Roche Holding AG, a Switzerland-based pharmaceutical company, introduced three new coagulation tests specifically designed for Factor Xa inhibitors. These innovations empower clinicians to more precisely evaluate the anticoagulation status of patients on direct Factor Xa inhibitors such as rivaroxaban and apixaban. They further assist clinical decision-making by accurately measuring the anti-Xa activity of apixaban, edoxaban, rivaroxaban, and heparin in critical situations like bleeding, overdose, or urgent surgery. Leveraging Roche’s reagent cassette technology on cobas t analyzers, these automated tests ensure high-quality outcomes, minimize manual processing, and optimize laboratory workflow efficiency.

Which Key Market Players Are Investing In Expansion And Innovation Of Direct Oral Anticoagulants (DOACs) Device Market?

Major companies operating in the direct oral anticoagulants (DOACs) device market are Pfizer Inc., Roche Diagnostics Corporation, Bristol-Myers Squibb Company, Siemens Healthcare GmbH, Becton Dickinson And Company, Boehringer Ingelheim International GmbH, Teva Pharmaceutical Industries Limited, Daiichi Sankyo Co. Ltd, Sysmex Corporation, Dr. Reddy’s Laboratories Limited, Werfen S.A., Alembic Pharmaceuticals Limited, Diagnostica Stago SAS, Helena Laboratories Corporation, iLine Microsystems S.L., Technoclone GmbH, Anthos Therapeutics Inc., FLoBio LLC, Perosphere Technologies Inc., and DOASENSE GmbH.

Download The Full Report For Exclusive Market Findings:

https://www.thebusinessresearchcompany.com/report/direct-oral-anticoagulants-doacs-device-global-market-report

Which Geographies Are Emerging As Strong Markets For The Direct Oral Anticoagulants (DOACs) Device Industry?

North America was the largest region in the direct oral anticoagulants (DOACs) device market in 2024. The regions covered in the direct oral anticoagulants (DOACs) device market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Request A Customized Version Of The Direct Oral Anticoagulants (DOACs) Device Market Report:

https://www.thebusinessresearchcompany.com/customise?id=27281&type=smp

Browse Through More Reports Similar to the Global Direct Oral Anticoagulants (DOACs) Device Market 2025, By The Business Research Company

Financial Services Global Market Report 2025

https://www.thebusinessresearchcompany.com/report/financial-services-global-market-report

Machine Learning Global Market Report 2025

https://www.thebusinessresearchcompany.com/report/machine-learning-global-market-report

Financial Analytics Global Market Report 2025

https://www.thebusinessresearchcompany.com/report/financial-analytics-global-market-report

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas +1 310-496-7795

Asia +44 7882 955267 & +91 8897263534

Europe +44 7882 955267

Email us at info@tbrc.info

Follow us on:

LinkedIn: https://in.linkedin.com/company/the-business-research-company

YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model

Claim your 30% discount on Global Market Reports with code ONLINE30. Limited time only.

Claim your 30% discount on Global Market Reports with code ONLINE30. Limited time only._x000D_

_x000D_

#What Is the Estimated Industry Valuation for the Direct Oral Anticoagulants (DOACs) Device Sector?#_x000D_

The market size of the direct oral anticoagulants (DOACs) device has seen substantial growth in the past few years. It is projected to increase from $30.10 billion in 2024 to $32.80 billion in 2025, registering a compound annual growth rate (CAGR) of 9.0%. The growth during the previous period has been driven by factors such as the increasing cases of cardiovascular diseases, higher incidence of atrial fibrillation, growing understanding of stroke prevention, rise in anticoagulant prescriptions, and the expansion of the elderly population._x000D_

_x000D_

In the forthcoming years, the market size for the direct oral anticoagulants (DOACs) device is projected to experience robust expansion. The value of this market is forecasted to reach $45.65 billion in 2029, growing at a compound annual growth rate (CAGR) of 8.6%. The surge in growth during the forecast period can be accredited to the increasing acceptance of personalized medicine, a change in preference for anticoagulant management at home, an escalated demand for quick diagnostic tools, growing knowledge about stroke prevention, and the development of healthcare infrastructure in emerging markets. Key trends foreseen during this period are the inclusion of smart sensors in monitoring devices, the creation of point-of-care direct oral anticoagulant testing tools, constant innovation in drug delivery methods, integration into recurring clinical procedures, and advances in technology relating to patient compliance tools._x000D_

_x000D_

#Download The Free Sample Report Here:#_x000D_

https://www.thebusinessresearchcompany.com/sample.aspx?id=27281&type=smp_x000D_

_x000D_

#What Forces Are Driving The Growth Of The Direct Oral Anticoagulants (DOACs) Device Market?#_x000D_

The surge in cardiovascular diseases is anticipated to fuel the expansion of the direct oral anticoagulants (DOACs) device market in the future. These cardiovascular disorders, which include a variety of conditions that affect the heart and blood vessels, often result in complications such as heart attacks, strokes, or other vascular system issues. Factors like sedentary lifestyles, weight gain, high blood pressure, and deteriorating cardiovascular function over time are leading to a rise in these disorders. Direct oral anticoagulants (DOACs) assist in managing these disorders by effectively reducing the stroke and blood clot risks in patients suffering from atrial fibrillation and providing steady anticoagulation, eliminating the need for regular blood tests. For example, the American Heart Association, a US-based nonprofit organization, reported that cardiovascular disease accounted for 941,652 fatalities in the US in 2022, a rise of over 10,000 from the 931,578 deaths reported in 2021. Consequently, the escalating occurrence of cardiovascular diseases, is stimulating the direct oral anticoagulants (DOACs) device market’s progression._x000D_

_x000D_

#How Is The Direct Oral Anticoagulants (DOACs) Device Industry Segmented Across Key Parameters?#_x000D_

The direct oral anticoagulants (DOACs) device market covered in this report is segmented_x000D_

_x000D_

1) By Product: Factor Xa Inhibitors, Direct Thrombin Inhibitors_x000D_

2) By Disease: Atrial Fibrillation, Deep Vein Thrombosis, Pulmonary Embolism, Heart Attacks, Post-Surgical Thromboprophylaxis, Other Diseases_x000D_

3) By Application: Stroke Prevention, Venous Thromboembolism Prevention, Treatment Of Acute Thrombotic Events, Long-Term Prophylaxis, Other Applications_x000D_

4) By End User: Hospitals, Ambulatory Surgical Centers, Specialty Clinics, Homecare Settings, Other End Users_x000D_

_x000D_

Subsegments:_x000D_

1) By Factor Xa Inhibitors: Rivaroxaban Monitoring Devices, Apixaban Monitoring Devices, Edoxaban Monitoring Devices, Betrixaban Monitoring Devices_x000D_

2) By Direct Thrombin Inhibitors: Dabigatran Etexilate, Dabigatran Mesylate_x000D_

_x000D_

#What Notable Trends Are Shaping The Direction Of The Direct Oral Anticoagulants (DOACs) Device Market?#_x000D_

Prominent firms in the direct oral anticoagulants (DOACs) market are prioritizing the creation of innovative solutions, such as automated coagulation assays, to enhance precision, productivity, and uniformity in monitoring direct oral anticoagulant levels in clinical labs. Automated coagulation assays are machine-conducted lab tests that determine the speed of blood clotting, assisting in the identification of bleeding or clotting issues. For instance, in February 2024, Roche Holding AG, a pharmaceutical firm based in Switzerland, introduced three novel coagulation tests developed specifically for Factor Xa inhibitors. These tests augment the capacity of clinicians to correctly assess the anticoagulation condition of patients consuming direct Factor Xa inhibitors like rivaroxaban and apixaban. These tests facilitate clinical decision-making by accurately gauging the anti-Xa activity of apixaban, edoxaban, rivaroxaban, and heparin in critical situations such as bleeding, overdose, or immediate surgery. Through the utilization of Roche’s reagent cartridge technology on cobas t analyzers, these automated tests provide top-quality results, reduce manual input, and accelerate lab workflow efficiency._x000D_

_x000D_

#Which Companies Currently Dominate The Competitive Landscape In The Direct Oral Anticoagulants (DOACs) Device Industry?#_x000D_

Major companies operating in the direct oral anticoagulants (DOACs) device market are Pfizer Inc., Roche Diagnostics Corporation, Bristol-Myers Squibb Company, Siemens Healthcare GmbH, Becton Dickinson And Company, Boehringer Ingelheim International GmbH, Teva Pharmaceutical Industries Limited, Daiichi Sankyo Co. Ltd, Sysmex Corporation, Dr. Reddy’s Laboratories Limited, Werfen S.A., Alembic Pharmaceuticals Limited, Diagnostica Stago SAS, Helena Laboratories Corporation, iLine Microsystems S.L., Technoclone GmbH, Anthos Therapeutics Inc., FLoBio LLC, Perosphere Technologies Inc., and DOASENSE GmbH. _x000D_

_x000D_

#Get The Full Report Here:#_x000D_

https://www.thebusinessresearchcompany.com/report/direct-oral-anticoagulants-doacs-device-global-market-report_x000D_

_x000D_

#Which Geographic Regions Are Driving Demand In The Direct Oral Anticoagulants (DOACs) Device Market?#_x000D_

North America was the largest region in the direct oral anticoagulants (DOACs) device market in 2024. The regions covered in the direct oral anticoagulants (DOACs) device market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa._x000D_

_x000D_

#Request For A Customized Report:#_x000D_

https://www.thebusinessresearchcompany.com/customise?id=27281&type=smp_x000D_

_x000D_

#About The Business Research Company:#_x000D_

_x000D_

With over 15000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Armed with 1,500,000 datasets, the optimistic contribution of in-depth secondary research, and unique insights from industry leaders, you can get the information you need to stay ahead in the game._x000D_

_x000D_

#Get in touch with us:#_x000D_

_x000D_

The Business Research Company: https://www.thebusinessresearchcompany.com/_x000D_

Americas +1 310-496-7795_x000D_

Asia +44 7882 955267 & +91 8897263534_x000D_

Europe +44 7882 955267_x000D_

Email us at info@tbrc.info_x000D_

_x000D_

#Follow us on:#_x000D_

_x000D_

LinkedIn: https://in.linkedin.com/company/the-business-research-company_x000D_

YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ_x000D_

Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model